Introduction {#sec1}
============

A unique and fundamental characteristic of malignant neoplastic cells is their ability to invade new tissues and metastasise. The first step in this process is the dissociation of some of these cells from the invasive front of the tumour, which is often associated with a transformation: either dedifferentiation or transdifferentiation. Several researchers have highlighted the histopathologic representation of this phenomenon using various terms, but the most accepted is tumour budding (TB), which has become relevant recently given TB's relationship with vascular invasion, metastasis, and prognosis in colorectal cancer \[[@cit0001]--[@cit0018]\]. In addition, it has been hypothesised that TB is a morphologic representation of the epithelial-mesenchymal transition (EMT) \[[@cit0019]\].

Most of the literature on this phenomenon has focused on colorectal carcinoma (CRC) as a single entity because both sites share characteristics and prognostic factors; however, several of these characteristics behave differently in colon tumours than in rectal tumours, so it is advisable that the two sites be analysed separately. For this review, we searched all the literature available about TB in CRC from 1950 to 2017 using the databases Medline and EMBASE without language restriction. In addition, we also used papers that were missed in the search but listed in the reference lists of the obtained papers. For the historical, subcellular, morphological aspects and histological evaluation, we used works carried out in CRC; for associations with clinical outcomes, only articles about rectal cancer were described.

Historic evolution {#sec2}
==================

The term TB is not new; it was first reported almost 70 years ago in Japan. The first mention was made by Imai \[[@cit0001]\], when he proposed the "CPL staging system" for cancer based on three parameters: 1) the "sprouting" (what we know today as TB) of tumour cells (C), 2) peritumoural stromal reaction (P), and 3) lymphovascular invasion (L). These observations were later reported to be useful in CRC \[[@cit0002]--[@cit0003]\]. Despite these first reports, these concepts disappeared from the literature until the 1980s, when it was reported that TB was strongly associated with lymph node metastases in gastric carcinoma and early CRC \[[@cit0004]--[@cit0007]\]*.* Later, during the 1990s, Hase *et al.* \[[@cit0008]\] demonstrated the association of TB with adverse clinicopathological factors such as tumour grade, tumour stage, and lymphovascular and perineural invasion, as well as laying the groundwork for the evaluation of TB. During the following years, little was studied until the middle 2000s, when a few studies about the morphological and molecular aspects of TB were published, expanding the knowledge about TB to other carcinomas such as breast, lung, oesophagus, and pancreas.

Tumour budding definition {#sec3}
=========================

Tumour budding definition has been a controversial issue throughout its development, and even nowadays, when there is a consensus about it \[[@cit0009]\]. Some researchers have defined TB as the presence or absence of single cells around a tumour invasive front, while others authors have counted them as the number of buds on the invading front, while several others have counted them as the number of buds on the intra-tumoural stroma, etc. \[[@cit0001]--[@cit0008]\]. Tumour budding cells are individual cells or small groups of up to four or five elements separated from their counterparts in the bulk of the main tumour ([Fig. 1](#f0001){ref-type="fig"}). The definition most widely used and adopted in the consensus is that TB is an isolated tumour cell or those in groups of up to four cells separated from the glands of the tumour invading front ([Table 1](#t0001){ref-type="table"} and [Appendix 1](#t0002){ref-type="table"}) \[[@cit0009]\].

###### 

Studies until 2017 about the evaluation of tumoural budding in rectal cancer specifically addressing rectal cancer or including the number of cases of rectal cancer when evaluating colorectal cancer

  Author (year)           Country                    Site C = colon (n), R = rectum (n)   Study period   Stage(AJCC)   Method    Budding definition   Tumour budding evaluation                                                          Interobserver Kappa
  ----------------------- -------------------------- ------------------------------------ -------------- ------------- --------- -------------------- ---------------------------------------------------------------------------------- ---------------------
  Hase (1993)             Japan                      C (449) / R (214)                    1970--1985     I--III        H&E       1--4 cells           Hase = negative/mild vs. moderate/severe                                           N.D.
  Goldstein (1999)        United States of America   R (73)                               --             I--III        H&E       Individual cells     Focal: \< 3 foci, moderate: 2--10 foci or \< 3 mm Diffuse: \> 10 foci or \> 3 mm   N.D.
  Ueno (2002a)            United Kingdom             R (638)                              1960--1969     I--III        H&E       1--4 cells           Ueno = No. foci/0.385 mm\<sup\>2\</sup\> Groups: 0--9 vs. \> 10 TB                 0.840
  Ueno (2002b)            Japan                      R (437)                              1981--1994     III           H&E       1--4 cells           Modified Ueno = No. foci/0.385 mm Groups: 0--4 vs. \> 5 TB                         N.D.
  Okuyama (2003b)         Japan                      R (83)                               1985--1997     II--III       H&E       \> 4 cells           Morodomi                                                                           0.938
  Ueno (2004)             Japan                      R (1114)                             1960--1980     I--III        H&E       1--4 cells           Ueno                                                                               N.D.
  Guzinska (2005)         Poland                     R (34)                               1999--2003     I--III        H&E       1--4 cells           Morodomi                                                                           N.D.
  Masaki (2005)           Japan                      R (72)                               1978--1995     I--III        H&E       1--4 cells           Mordodomi                                                                          N.D.
  Prall (2005)            Germany                    C (124) / R (58)                     1994--1999     I--II         IHC       1--4 cells           0--24 TB vs. \> 25 TB                                                              0.874
  Shinto (2005)           Canada                     C (53) / R (20)                      1983--1994     I--III        H&E       1--4 cells           Ueno                                                                               N.D.
  Kazama (2006)           Japan                      C (42) / R (14)                      1990--2001     I--III        H&E/HC    1--4 cells           Morodomi                                                                           N.D
  Mazaki (2006)           Japan                      C (62) / R (14)                      1992--2002     I--III        H&E       1--4 cells           Morodomi                                                                           N.D.
  Choi (2007)             Korea                      R (244)                              1995--1999     I--III        H&E       1--4 cells           Quartiles 0--3, 4--5, 6--10, or 11--38 TB                                          0.760
  Prall (2007)            Germany                    C (59) / R (36)                      2002--2004     I--III        H&E       1--4 cells           No foci/0.332 mm\<sup\>2\</sup\>                                                   N.D.
  Homma (2010)            Japan                      R (65)                               2000--2007     I and III     H&E       1--4 cells           Hase                                                                               N.D.
  Karamitopoulou (2010)   Greece                     C (180) / R (28)                     2004--2006     I--III        H&E       1--4 cells           0--5 vs. 6 or more                                                                 N.D.
  El-Gendi (2011)         Egypt                      C (37) / R (7)                       2007--2009     I--III        H&E/IHC   1--4 cells           Ueno                                                                               N.D.
  García-Solano (2011)    Spain                      C (149) / R (13)                     --             I--IV         H&E       1--4 cells           Ueno                                                                               0.863
  Kevans (2011)           Ireland                    C (188) / R (70)                     1990--2004     II            H&E       1--4 cells           Morodomi                                                                           N.D.
  Syk (2011)              Sweden                     R (129)                              1995--2000     I--III        IHC       1--4 cells           0--24 vs. 25 or more                                                               N.D.
  Sert Bektas (2012)      Turkey                     C (50) / R (23)                      2003--2007     I--III        H&E       1--4 cells           Ueno                                                                               N.D.
  Du (2012)               China                      R (96)                               2001--2005     III           H&E       0--1 cells           Ueno in 0.949 mm\<sup\>2\</sup\>                                                   0.793
  Caie (2014)             United Kingdom             C (33) / R (17)                      1996--2003     I--III        H&E       1--4 cells           0, 1--2, and \> 2 TB                                                               N.D.
  Dawson (2013)           Switzerland                C (162) / R (26)                     2002--2006     I--III        H&E       1--4 cells           Ueno                                                                               N.D.
  Satoh (2014)            Japan                      C (88) / R (51)                      2005--2009     I--III        IHC       1--4 cells           Grade 1: 0--4, Grade 2: 5--9, Grade 3: 10 or more. TB+ with con Grade 2--3         N.D.
  Koelzer (2015)          Grece                      C (180) / R (27)                     2004--2007     I--III        IHC       1--4 cells           No in 10 high-power fields                                                         N.D.
  Yamada (2017)           Japan                      C (41) / R (60)                      2005--2010     I--III        IHC       1--4 cells           Modified Ueno                                                                      N.D.

H&E -- haematoxylin and eosin; IHC -- immunohistochemistry; TB -- buds; No -- number

###### 

Characteristics of the studies regarding the evaluation of tumoural budding in the literature until 2017

  Author (year)             Country                    *n*    Site C = colon (*n*), R = rectum (*n*)   Study period   Stage (AJCC)   Method      Definition of budding   Tumour budding evaluation                                                                    Interobserver Kappa
  ------------------------- -------------------------- ------ ---------------------------------------- -------------- -------------- ----------- ----------------------- -------------------------------------------------------------------------------------------- ---------------------
  Hase (1993)               Japan                      663    C (449) R (214)                          1970--1985     I--III         H&E         1--4 cells              Hase = negative/mild vs. moderate/severe                                                     N.D.
  Araki (1993)              Japan                      87     CR                                       1980--1972     I              H&E         1--4 cells              Morodomi: \> 1 TB                                                                            N.D.
  Goldstein (1999)          United States of America   73     R                                        --             I--III         H&E         Individual cells        Focal: \< 3 foci, Moderate: 2--10 foci or \< 3 mm Extent: \> 10 foci or \> 3 mm              N.D.
  Sordat (2000)             Switzerland                52     CR                                       2000           --             H&E         1--4 cells              Hase                                                                                         N.D.
  Masaki (2001)             Japan                      51     CR                                       1994--2000     I--III         H&E         Individual cells        Hase                                                                                         N.D.
  Ueno (2002a)              United Kingdom             638    R                                        1960--1969     I--III         H&E         1--4 cells              Ueno = No. foci/0.385 mm Groups: 0--9 vs. \> 10 TB                                           0.840
  Ueno (2002b)              Japan                      437    R                                        1981--1994     III            H&E         1--4 cells              Modified Ueno = No. foci/ 0.385 mm Groups: 0--4 vs. \> 5 TB                                  N.D.
  Jass (2003)               Australia                  95     CR                                       1994--2000     I--III         H&E         Individual cells        Morodomi                                                                                     N.D.
  Okuyama (2003a)           Japan                      196    C                                        1985--1997     II--III        H&E         1--5 cells              Morodomi                                                                                     N.D.
  Okuyama (2003b)           Japan                      83     R                                        1985--1997     II--III        H&E         \> 4 cells              Morodomi                                                                                     0.938
  Tanaka (2003)             Japan                      138    C                                        1981--1993     II             H&E         1--4 cells              Hase                                                                                         N.D.
  Guzinska (2003)           Poland                     57     CR                                       1999--2003     II--III        H&E         1--4 cells              Morodomi                                                                                     N.D.
  Guzinska (2004)           Poland                     40     CR                                       --             II--III        H&E         1--4 cells              Morodomi                                                                                     N.D.
  Ueno (2004)               Japan                      1114   R                                        1960--1980     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Park (2005)               Korea                      274    C                                        1995--1999     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Guzinska (2005)           Poland                     34     R                                        1999--2003     I--III         H&E         1--4 cells              Morodomi                                                                                     N.D.
  Masaki (2005)             Japan                      72     R                                        1978--1995     I--III         H&E         1--4 cells              Mordodomi                                                                                    N.D.
  Prall (2005)              Germany                    182    C (124) R (58)                           1994--1999     I--II          IHC         1--4 cells              0--24 TB vs. \> 25 TB                                                                        0.874
  Wang (2005)               China                      159    CR                                       1969--2002     I and III      H&E         \> 4 cells              Morodomi                                                                                     N.D.
  Shinto (2005)             Canada                     73     C (53) R (20)                            1983--1994     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Hörkkö (2006)             Finlandia                  386    CR                                       1986--1996     I--III         H&E         1--4 cells              Morodomi                                                                                     0.707
  Kazama (2006)             Japan                      56     C (42) R (14)                            1990--2001     I--III         H&E & IHC   1--4 cells              Morodomi                                                                                     N.D.
  Mazaki (2006)             Japan                      76     C (62) R (14)                            1992--2002     I--III         H&E         1--4 cells              Morodomi                                                                                     N.D.
  Guzinska (2006)           Poland                     55     CR                                       --             I--III         H&E         1--4 cells              Morodomi                                                                                     N.D.
  Shinto (2006)             Japan                      136    CR                                       1989--1993     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Choi (2007)               Korea                      244    R                                        1995--1999     I--III         H&E         1--4 cells              Quartiles (0--3, 4--5, 6--10, or 11--38 TB)                                                  0.760
  Prall (2007)              Germany                    95     C (59) R (36)                            2002--2004     I--III         H&E         1--4 cells              No. foci/0.332 mm\<sup\>2\</sup\>                                                            N.D.
  Yasuda (2007)             Japan                      86     CR                                       --             II--IV         H&E         Individual cells        Morodomi                                                                                     N.D.
  Zlobec (2007)             Canada                     1164   CR                                       --             I--III         H&E         Individual cells        Morodomi                                                                                     N.D.
  Kanazawa (2008)           Japan                      159    CR                                       1996--2001     II--IV         H&E         Individual cells        Mild (1/3 invasive front) vs. moderate (1/3--2/3) vs. strong (\> 2/3)                        N.D.
  Nakamura (2008)           Japan                      200    C                                        1986--1998     II             H&E         Individual cells        Kanazawa                                                                                     N.D.
  Yamauchi (2008)           Japan                      164    CR                                       1991--2001     I and III      H&E         1--4 cells              0--4 vs. 5--9 vs. \> 10 TB                                                                   N.D.
  Ohtsuki (2008)            Japan                      149    CR                                       1997--2000     I--III         H&E/IHC     1--4 cells              H&E: 0--4 vs. 5 or more IHC: 0--15 vs. 16 or more                                            N.D.
  Lugli (2009)              Switzerland                273    CR                                       1987--1996     I--III         IHC         1--5 cells              0--15 TB vs. \> 16 TB                                                                        N.D.
  Ogawa (2009)              Japan                      98     CR                                       1995--2003     I and III      IHC         1--4 cells              0--8 TB vs. \> 9 TB                                                                          N.D.
  Suzuki (2007)             Japan                      124    CR                                       1990--2004     I--III         H&E/IHC     1--4 cells              Ueno                                                                                         H&E: 0.41 IHC: 0.53
  Wang (2009)               Irlanda                    128    CR                                       1990--2004     II             H&E         1--4 cells              Morodomi                                                                                     0.51
  Homma (2010)              Japan                      65     R                                        2000--2007     I and III      H&E         1--4 cells              Hase                                                                                         N.D.
  Karamitopoulou (2010)     Grece                      208    C (180) R (28)                           2004--2006     I--III         H&E         1--4 cells              0--5 vs. 6 or more                                                                           N.D.
  Sy (2010)                 Australia                  477    C                                        1971--2001     III            H&E         1--4 cells              Per mm\<sup\>2\</sup\>. Groups: 0--8 vs. 9 or more                                           N.D.
  Kajiwara (2010)           Japan                      244    CR                                       1985--2005     I and III      H&E         1--4 cells              0--8 TB vs. \> 9 TB                                                                          N.D.
  Komori (2010)             Japan                      111    CR                                       1990--2004     I and III      H&E         1--4 cells              Modified Ueno                                                                                N.D.
  Tateishi (2010)           Japan                      322    CR                                       1992--2005     I and III      H&E         1--4 cells              \> 1 based on Ueno                                                                           N.D.
  Zlobec (2010)             Switzerland                43     CR                                       --             IV             H&E         1--4 cells              0--14 vs. 15 or more                                                                         0.6
  El-Gendi (2011)           Egypt                      44     C (37) R (7)                             2007--2009     I--III         H&E/IHC     1--4 cells              Ueno                                                                                         N.D.
  García-Solano (2011)      Spain                      162    C (149) R (13)                           --             I--IV          H&E         1--4 cells              Ueno                                                                                         0.863
  Kevans (2011)             Ireland                    258    C (188) R (70)                           1990--2004     II             H&E         1--4 cells              Morodomi                                                                                     N.D.
  Lugli (2011)              Switzerland                289    CR                                       --             I--IV          IHC         Individual cells        0--5 vs. 6 or more                                                                           N.D.
  Syk (2011)                Sweden                     129    R                                        1995--2000     I--III         IHC         1--4 cells              0--24 vs. 25 or more                                                                         
  Khanh (2012)              Japan                      209    C (114) R (92)                           1998--2005     II--IV         H&E         Not defined             Not defined                                                                                  N.D.
  Kye (2012)                Corea                      55     CR                                       2007--2010     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Betge (2012)              Austria                    120    CR                                       1954--2005     II             H&E         1--4 cells              Ueno                                                                                         N.D.
  Nakadoi (2012)            Japan                      499    CR                                       1981--2008     I and III      H&E         1--5 cells              Modified Ueno                                                                                N.D.
  Sert Bektas (2012)        Turkey                     73     C (50) R (23)                            2003--2007     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Canney (2012)             Ireland                    77     C                                        1996--2006     II             H&E         Individual cells        Morodomi                                                                                     N.D.
  Wada (2012)               Japan                      120    CR                                       1995--2005     I and III      H&E         1--4 cells              Modified Ueno                                                                                N.D.
  Zlobec (2012)             Switzerland                127    CR                                       1987--1996     I--III         IHC         1--5 cells              \> 5 TB                                                                                      N.D.
  Du (2012)                 China                      96     R                                        2001--2005     III            H&E         0--1 cells              Ueno in 0.949 mm\<sup\>2\</sup\>                                                             0.793
  Oshiro (2012)             Japan                      213    CR                                       1990--2007     --             H&E         Individual cells        Ueno                                                                                         N.D.
  Karamitopoulou (2013)     Grece                      215    CR                                       --             I--IV          IHC         1--4 cells              Average in 10 fields                                                                         0.5 a 0.87
  Horcic (2013)             Switzerland                105    C                                        --             I--II          IHC         1--4 cells              Compares several methods vs. average on 10 high-power fields                                 Several
  Khanh do (2013)           Japan                      206    CR                                       1998--2005     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Umemura (2013)            Japan                      142    CR                                       --             I--III         H&E         1--4 cells              Modified Ueno                                                                                N.D.
  Caie (2014)               United Kingdom             50     C (33) R (17)                            1996--2003     I--III         H&E         1--4 cells              0, 1--2, and \> 2 TB                                                                         N.D.
  Dawson (2014)             Atenas                     188    C (162) R (26)                           2002--2006     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Nishida (2014)            Japan                      265    CR                                       2000--2011     I and III      H&E         1--4 cells              Modified Ueno                                                                                N.D.
  Huh (2014)                Corea                      543    CR                                       2007--2009     I and III      H&E         1--4 cells              \> 5 TB                                                                                      N.D.
  Lai (2014)                China                      135    C                                        1999--2007     II             H&E         1--4 cells              Ueno                                                                                         N.D.
  Ryu (2014)                Corea                      179    CR                                       2003--2012     I and III      H&E         1--4 cells              Modified Ueno                                                                                N.D.
  Satoh (2014)              Japan                      139    C (88) R (51)                            2005--2009     I--III         IHC         1--4 cells              Grade1: 0--4, Grade 2: 5--9, Grade 3: 10 or more TB+ with con Grade 2--3                     N.D.
  Gilardoni (2015)          Italy                      196    C                                        2006--2009     I--II          H&E         1--4 cells              Modified Ueno                                                                                N.D.
  Macias-García (2015)      Spain                      97     CR                                       2000--2011     I              H&E         1--4 cells              Ueno                                                                                         N.D.
  Barresi (2016)            Italy                      82     CR                                       --             II             H&E         1--4 cells              Modified Ueno                                                                                N.D.
  Mezheyeuski (2015)        Poland                     57     CR                                       1999--2003     I--III         H&E         1--4 cells              Morodomi                                                                                     N.D.
  Graham (2015)             USA                        533    CR                                       1986--2002     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Koelzer (2015)            Grece                      207    C (180) R (27)                           2004--2007     I--III         IHC         1--4 cells              No. in 10 high-power fields                                                                  N.D.
  Righi (2015)              Italy                      479    CR                                       2000--2011     I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Miyachi (2016)            Japan                      653    CR                                       2001--2014     I              H&E         1--4 cells              Modified Ueno                                                                                N.D.
  Kai (2016)                Japan                      40     CR                                       2006--2013     I              IHC         1--4 cells              Grade 1: 0--4, Grade 2: 5--9, Grade 3: 10 or more                                            H&E: 0.33 IHC: 0.42
  Max (2016)                Austria                    381    CR                                       --             I--III         H&E         1--4 cells              Ueno                                                                                         N.D.
  Okamura (2016)            Japan                      256    CR                                       1981--2009     I--III         IHC         1--4 cells              Ueno                                                                                         N.D.
  Van Wyk (2016)            Scotland                   303    CR                                       1997--2008     I--III         H&E         1--4 cells              Average in 10 high-power fields                                                              N.D.
  Baltruskeviciene (2017)   Lithuania                  44     CR                                       2011--2014     IV             H&E         1--4 cells              Average in 10 high-power fields (0--9 vs. 10 or more TB)                                     N.D.
  Forse (2017)              Canada                     172    CR                                       1992--2010     I--III         IHC         1--4 cells              Average in 10 high-power fields (0--24 vs. 25 or more TB)                                    N.D.
  Yamada (2017)             Japan                      101    C (41) R (60)                            2005--2010     I--III         IHC         1--4 cells              Modified Ueno                                                                                N.D.
  Knudsen (2017)            Denmark                    58     CR                                       2000--2008     II--III        H&E         1--4 cells              Ueno                                                                                         N.D.
  Rieger (2017)             Switzerland                215    CR                                       2002--2011     I--III         IHC         1--4 cells              Average in 10 high-power fields of 0.238 mm\<sup\>2\</sup\> each. Groups: 0--8 and \> 8 TB   N.D.

N.D. -- nof defined; No. -- number of

![**A)** Morphology of tumour budding. Note several individual cells (tumour budding cells, arrows) are detached along the infiltrative margin of the tumour. Haematoxylin and eosin, 40×. **B)** Several neoplastic cells infiltrating the stroma (arrows) in individual units are observed. Haematoxylin and eosin, 400×](WO-22-77043-g001){#f0001}

Grading tumour budding {#sec4}
======================

Several of the first classifications of the TB were subjective, such as those of Hase *et al.* \[[@cit0008]\], who presented a two-level system comparing none or "minimal" vs. "moderate" or "severe". Goldstein *et al.* \[[@cit0010]\] determined TB as absent or focal when there were \< 3 "focus of budding", moderate when there were 2 to 10 foci or a linear extension of \< 3 mm, and extensive when there were\> 10 foci or had an extension \> 3 mm. Nakamura *et al.* \[[@cit0011]\] proposed a four-level method (none, mild \< 1/3, moderate 1/3 to 2/3, and severe \> 2/3). These systems are subjective and were used in a few works \[[@cit0012]--[@cit0015]\].

The first quantitative method was proposed by Morodomi \[[@cit0006]\], where it is simply qualified as present (≥ 1 tumour bud for high-power field) or absent. This method is widely used because of its practicality and good interobserver concordance (kappa index \[κ\], κ = 0.938) \[[@cit0016]\]. Ueno *et al.* \[[@cit0017], [@cit0018]\] proposed two quantitative methods based on the hot spot of the TB using a microscopy lens of 20× magnification in one observation field (accounting for an area of 0.785 mm^2^) or of 25× (area of 0.385 mm^2^), which are perhaps the most widely used methods ([Table 1](#t0001){ref-type="table"}) with some variation in both the cut-off point to set up the prognostic groups and in the evaluation area.

Wang *et al.* \[[@cit0020]\] presented a method based on the selection of five random areas of 0.95 mm^2^ and the subsequent evaluation of each area for the presence of any bud. A positive case would be one where there is ≥ 50% of the areas with at least one bud, but this method has not been replicated.

Finally, one study determined that the median time per slides evaluating five fields in an area of 0.945^2^ ranged from 1.3 to 1.7 minutes (range of 0.4 to 2.7 minutes). Using a rapid count method and scoring the TB as presence vs. absence, the median time for evaluation ranged from 0.49 to 0.83 minutes (range 0.3 to 1.7). The difference between the first method and the rapid count was significant (*p* \< 0.001) \[[@cit0020]\].

Reproducibility of the determination of tumour budding {#sec5}
======================================================

The minimum requirements for an ideal prognostic parameter are its reproducibility, availability, and quality control. Also, the system categories must have a real predictive value beyond the recognised prognostic systems. Studies addressing reproducibility have shown that it varies much, probably reflecting differences in the definition and quantification method of TB. Ueno *et al.* \[[@cit0018]\] demonstrated a substantial agreement between observers (κ = 0.646) when patients were stratified into four groups according to the degree of TB; however, the level of concordance improved using stratification into one of two groups (κ = 0.84). Zlobec *et al.* \[[@cit0021]\], during a classification into two grades, found a κ of 0.6. Okuyama *et al.* \[[@cit0022]\], in a classification based on two categories (absence versus presence of TB), found an excellent concordance (κ = 0.938); however, using the same classification, the studies of Hörkkö *et al.* \[[@cit0023]\] and Wang *et al.* \[[@cit0020]\] found a κ of 0.760 and 0.51, respectively.

The use of immunohistochemistry (IHC) with cytokeratin allows the easy identification and rapid classification of TB and improves reproducibility ([Fig. 2](#f0002){ref-type="fig"}). Prall *et al.* \[[@cit0024]\] evaluated tumour budding with IHC using cytokeratin and reported a good intra-observer agreement with a κ of 0.874, Karamitopoulou *et al.* \[[@cit0025]\] demonstrated an interobserver agreement of 0.5 to 0.87 depending on the method and the number of observers. In two studies, the interobserver concordance between haematoxylin and eosin (H&E) and IHC were specifically evaluated, and an improved κ from 0.41 to 0.53 \[[@cit0026]\] and from 0.33 to 0.42 \[[@cit0027]\] was found with the use of IHC, in addition to demonstrating that IHC assessment is better for less experienced pathologists. Similarly, Ohtsuki *et al.* \[[@cit0028]\] found that the detection and evaluation of TB by IHC is an independent prognostic factor for recurrence. Rieger *et al.* \[[@cit0029]\] found that the evaluation of TB with IHC in a single hot spot had a similar diagnostic performance when compared with the evaluations in 10 fields, which suggests that it is more practical. Conversely, Okamura *et al.* \[[@cit0030]\] found that the evaluation of TB by H&E was a significant predictor of lymph node metastasis, while the detection by IHC was not. Finally, several works comparing different methods of grading TB showed that interobserver reproducibility is highly variable depending on the cut points, the number of categories, the number of observers, and the method used (H&E, IHC, using software, and telepathology) \[[@cit0031] --[@cit0033]\].

![Immunohistochemistry with cytokeratin cocktail highlights tumour budding cells (blue arrows) and allow to evaluate the TB more rapidly and easily. CKAE1/AE3 contrasted with haematoxylin, 100×](WO-22-77043-g002){#f0002}

Morphology of tumour budding {#sec6}
============================

It has been determined that TB is made up of individual cells or small groups of cells ([Fig. 1](#f0001){ref-type="fig"}) \[[@cit0018], [@cit0019], [@cit0025]\]. Although the morphology of TB suggests an energetic migration of cells identified as whole cells or small cytoplasmic fragments, it actually appears that TB consists of a migration of projections originating in solid structures or glands of the invading front, conformed by cellular aggregates of even a size superior to the four or five cells under the definition of TB \[[@cit0034], [@cit0035]\]. These projections are well-organised with a basal lamina that abuts the outer circumference; they have intercellular junctions and microvilli (abortive) as well as an envelope of myofibroblasts. This shows that the neoplastic gland is invading, advancing through long extensions like dendritic extensions, called "podias" \[[@cit0035] --[@cit0037]\] or "tubular invasion pole" \[[@cit0038]\], a fact that has been well demonstrated in studies that have made serial sections of the tumour \[[@cit0039]\].

However, this organised state seems to be focally disturbed: myofibroblasts may be withdrawn or absent, ultra-structurally, there is an absence of basal lamina, and the cytoplasmic junctions of the tumour cells come into direct contact with the extracellular matrix (i.e. the intercellular junctions are lost) \[[@cit0040]\]. Despite these findings, it has also been observed through experimental models and with 3D reconstruction that there is indeed a true migration of individual cells from the main body of the tumour to the stroma, and it has been calculated that the theoretical proportion of individual cells is 0.003% \[[@cit0041]\].

Association of tumoural budding with histopathological characteristics of rectal carcinoma {#sec7}
==========================================================================================

In rectal cancer, the definition of high-risk TB depends on the study, but generally corresponds to the presence of \> 10 buds per unit area and has been identified between 30.1% \[[@cit0018]\] and 92% \[[@cit0042]\]; it is associated with pathological characteristics such as poor tumour differentiation, pathological stages T3 and T4, lymph node metastases (both the total number and the tumour volume), less lymphocyte infiltration, and greater frequency of lymphatic and venous vascular invasion \[[@cit0010], [@cit0018], [@cit0022], [@cit0043], [@cit0044]\]. There has no histopathological subtype associated specifically with high-grade tumour budding; indeed, the TB evaluation should be performed in any histologic subtype, especially in the conventional tubular subtype \[[@cit0009]\].

Inflammation {#sec7.1}
------------

Several studies have shown that lymphocytes within the tumour stroma (intratumoural lymphocytes -- ITL) and around the tumour along the invasive margin (peritumoural lymphocytes) are significantly related to the best overall and disease-specific survival in multivariate analyses \[[@cit0045] --[@cit0047]\].

It has been shown that TB is inversely correlated with the infiltration of CD8+ T cells, suggesting a possible defence, based on T cells, against the infiltration of TB cells in the tumour microenvironment of the CCR \[[@cit0048]\]. Once the tumour buds are formed, they are able to evade the immune response of the host directed by the CD8+ T cells, in addition to the loss of Major Histocompatibility Complex-I (MHC-I) expression identified in these cells \[[@cit0033]\], which supports the notion that immune evasion by the primary tumour can ease the invasion process. Conversely, the same authors demonstrated that patients capable of developing a functional immune response that includes the activation of CD8+ T cells and the expression of TIA1 cytotoxic granule-associated RNA binding protein (TIA1) may be able to destroy cancer cells that express MHC-I on the invasive front. These authors found an almost complete absence of budding cells in the tumour stroma of cases with increased expression of CD8+ and TIA1+ in the stroma as well as MHC-I in the invading front. Finally, two studies show that the density of the inflammatory infiltrate correlates proportionally with a better prognosis and a lower degree of TB \[[@cit0049], [@cit0050]\].

Tumour regression {#sec7.2}
-----------------

Very few studies had addressed the significance of TB in preoperative biopsies of patients receiving preoperative chemoradiotherapy. Lugli *et al.* \[[@cit0051]\] found that patients with a high degree of TB showed an increased rate of pathological complete response compared with patients with lower degree of TB. We also confirmed this finding in a series of 216 cases, in which patients with low degree were associated with more pathologic complete response (odds ratio 2.52, 95% confidence interval (95% CI) = 1.366--4.894, *p* = 0.025, manuscript under review). The evaluation in biopsies is well-designed "intratumoural budding" and has been associated with the same adverse clinicopathological features that a high degree of TB in both colon and rectum \[[@cit0051]\], unfortunately, it was not considered in the TB consensus \[[@cit0009]\].

Microsatellite instability {#sec7.3}
--------------------------

Tumour budding is very rare in cancers that have a deficiency of DNA mismatch repair proteins (MMR) \[[@cit0051]--[@cit0053]\]. Colorectal cancers with microsatellite instability (MSI) have more ITL, more peritumoural lymphocytes, and more peritumoural lymphoid aggregates when compared to stable CRC in microsatellites. These factors contribute to the lower occurrence of TB in the CRC with MSI \[[@cit0051], [@cit0052]\].

Tumour budding and prognosis in rectal carcinoma {#sec8}
================================================

The association of high TB with a decrease in overall survival has been demonstrated in studies of stages I to III that did not receive preoperative treatment with chemotherapy or radiotherapy. Ueno *et al.* \[[@cit0018]\] found a five-year overall survival of 84% in patients with \< 10 tumour buds compared to 40.7% in those who had ≥ 10 (*p* = 0.0001), and in the multivariate analysis, they found an odds ratio for the deaths of 18.49 (95% CI = 1.45--2.68, *p* \< 0.0001). Okuyama *et al.* \[[@cit0022]\] also found a lower five-year survival in patients with high TB (51.8% vs. 85.0%, *p* \< 0.002). In a sub-analysis, the stage II showed a five-year survival of 71.3% vs. 89.7% (*p* \< 0.03), and stage III showed 37.8% vs. 62.5% (*p* = 0.396). In the multivariate analysis, they found an odds ratio for the death of 2858 (95% CI = 1.121--7.287, *p* \< 0.03). Furthermore, Choi *et al.* \[[@cit0042]\] found a five-year survival of 76.7% for patients with ≤ 10 buds compared to 47.2% for those with \>10 buds (*p* \< 0.0001). On the other hand, Du *et al.* \[[@cit0054]\] studied patients in stage III post chemo-radiotherapy and found that patients with grades 2 and 3 of Ryan's tumour regression stage had a worse five-year survival in the group with high-TB (55.6% vs. 87.5%, *p* \< 0.001), and in the multivariate analysis, the absence of TB was associated with a lower risk of death (OR = 0.177, 95% CI = 0.069--0.454, *p* \< 0.001). However, Bhangu *et al.* \[[@cit0055]\] found no association of TB with survival in patients with preoperative chemo- and radiotherapy. Finally, high TB has been associated with higher recurrence rates \[[@cit0042], [@cit0056], [@cit0057]\].

Molecular characteristics of tumour budding {#sec9}
===========================================

Tumour budding cells show properties similar to stem cells -- similar to even the gastrulation process within embryogenesis -- including the potential to re-differentiate both in the primary tumour and in metastatic sites \[[@cit0058]\]. It is also suggested that their phenotypic and morphological characteristics are dynamic and reversible due to epigenetic control.

The epithelial cells are normally contained within the basal membranes of the glandular structures called the "capsule" by some authors \[[@cit0039]\]. The focal degeneration of the capsule, due to age or disease, attracts lymphocytes that degrade them, resulting in a focal rupture. If the epithelial cells that cover the defect have terminal differentiation, there will be no cell division; this will be minimal, or the basement membrane will be repaired. However, if focal disruption occurs in a region of the basement membrane where the progenitor cells and/or tumour stem cells are, these cells have the opportunity to proliferate, causing their "budding" through the defect and later growth in the surrounding stroma \[[@cit0059]--[@cit0061]\]. Once proliferating epithelial buds are formed, their interaction with lymphocytes leads to an early pathway for metastasis. These observations were made in breast and prostate cancer tissues, where the epithelial cells are surrounded not only by a basement membrane but also by a well-organised layer of myoepithelial cells. This layer of cells exists in the rectal crypts; however, not enough attention has been paid to it \[[@cit0062]\].

As the lymphocytes infiltrate the tumour buds, they disrupt intercellular junctions and surface adhesion molecules, facilitating the dissociation of some cells and favouring TB. During this process, lymphocytes and tumour cells can form stable pairings (called tumour lymphocyte chimeras) through simple membrane fusion that does not trigger phagocytosis or the destruction of tumour cells \[[@cit0063]\]. This fusion can be mediated by the binding of the antigen associated with the lymphocyte expressed in immune cells and integrins in tumour cells \[[@cit0064]\]. A theory about metastasis is that this coupling allows the tumour cells to take advantage of the natural ability of the lymphocyte to migrate and break down cellular barriers to invade and travel to distant organs where the pair may then extravasate and grow \[[@cit0064]\].

Loss of intercellular adhesion and the epithelial-mesenchymal transition {#sec9.1}
========================================================================

The β-catenin protein, a membranal intercellular adhesion protein, has been implicated in the development of TB. It accumulates in the nucleus of the CRC cells of the invasive front, especially in undifferentiated or mesenchymal cells \[[@cit0047], [@cit0065] --[@cit0068]\]. This accumulation leads to the activation of the Wnt signalling pathway and other oncogenic events \[[@cit0069]\] in cells that are positive to CD44 \[[@cit0065]\] and laminin 5γ2 \[[@cit0012]\]. However, the TB process is largely restricted to the invasive margin, where the interaction between the malignant epithelium and the stromal elements occurs, suggesting that a TB phenotype is also driven by growth signals derived from mesenchymal cells \[[@cit0020], [@cit0052]\].

Several authors investigating the invasive front of CRC have used the term epithelial-mesenchymal transition (EMT), which characterises tumour invasion by dedifferentiated colorectal carcinoma cells. This process, which occurs physiologically during embryological development (EMT type I), has also been associated with tissue reparation (EMT type II) and tumour invasion (EMT type III). The cells in EMT lose their epithelial phenotype and acquire a mesenchymal phenotype (acquiring a fusiform morphology, they become mobile and begin to express markers including fibronectin and vimentin) \[[@cit0070] --[@cit0073]\] as well as lysosomal proteases such as cathepsin D and B \[[@cit0074]\]. Cathepsin D, as an endopeptidase, degrades many intracellular and endocytosed proteins as well as extracellular matrix (ECM) and basal epithelial proteins \[[@cit0075]\]. Cathepsin B often increases specifically in the invasive border of the carcinoma where the granules containing cathepsin B are located on the internal basal surface of the plasma membrane of neoplastic cells, contrary to normal cells that are located perinuclearly \[[@cit0076]\]. Degradation of the ECM is a very important step for tumour progression because the invasion of tumour cells implies a local proteolysis. Matrix metalloproteinase-9 (MMP-9) and metalloproteinase-2 (MMP-2) play a similar role, and it is suggested that the degradation of the basal membrane and the ECM by cathepsins and MMP-9 at the site of infiltration is the first stage of cancer invasion \[[@cit0077], [@cit0078]\]. Emmert-Buck *et al.* \[[@cit0079]\], who used a microdissection technique to determine the levels of enzymatic activity in specific microscopic areas of human colon cancer, found that gelatinase A and cathepsin B activities were positively regulated in the invasion fronts of invasive colon tumours.

Despite the postulations described before, the EMT in CRC cells has not been well demonstrated.

Tumour budding and DNA integrity {#sec9.2}
--------------------------------

Microsatellite instability is associated with a high-level CpG island methylation phenotype (CIMP-H), which can occur in up to 40% of cancers, and both MSI and CIMP-H often share clinicopathological and molecular features such as tumour localisation, poor differentiation, BRAF mutation, and possibly an increase of ITL CD8+ \[[@cit0080]\]. Although, typically, patients with MSI tumours have fewer metastases and benefit from a prolonged survival time, the prognosis for patients with CIMP-H tumours is often poor. One hypothesis to explain this apparent contradiction is that CIMP-H could promote a high-grade TB phenotype. Also, CIMP-H has been linked to the methylation of O6-methylguanine-DNA methyltransferase (MGMT), a gene that acts to repair inappropriately methylated guanine residues in DNA. The hypermethylation of the MGMT promoter occurs as an early event in colorectal carcinogenesis and is part of the alternative route of tumourigenesis that begins with the mutation of adenomatous colonic polyposis, a trigger of the EMT that causes activation of the Wnt pathway, the nuclear translocation of β-catenin, and the loss of E-cadherin (all characteristics of the high-grade TB phenotype) \[[@cit0081]\].

Tumour budding and other genes {#sec9.3}
------------------------------

In CRC cells, *RAS* signalling is important for EMT. The normal non-mutated RAS proteins are active in response to growth factors that bind to tyrosine kinases of the membranous receptor. In a signalling cascade involving the phosphorylation of extracellular mitogen-activated kinases, the signal is transmitted to the nucleus where it activates the transcription factors that influence the control of cell division (e.g. *c-Jun, c-Myc, c-Fos*). Alternatively, *RAS* activated through phosphoinositol 3-kinase (PI3K) acts on the actin filaments within the cells. Accordingly, processes as diverse as cell proliferation and modulation of cell shape and cell migration are stimulated by RAS-mediated signalling. In CRC, the gene is known to contain activating point mutations in 30% of the tumours \[[@cit0082], [@cit0083]\].

Cell proliferation and cell death {#sec9.4}
---------------------------------

TB cells have shown low proliferation, detected by ki67 and by caspases. Rubio *et al.* \[[@cit0084]\] demonstrated a low ki67-index in these cells accompanied by positive regulation of cyclin D1, and p16 cell cycle arrest mediators; furthermore, genes encoding these proteins are regulated by β-catenin, and this is a mechanism of cellular arrest induced by EMT. The p16 protein acts as a direct inhibitor of cyclin D1 promoting the arrest of the cell cycle, and it has been suggested that it also binds to cyclin-dependent kinase 4 (CDK4), is required for the activation of cyclin D1, and blocks its transport to the nucleus. In the absence of CDK4, cyclin D1 forms an inactive complex with CDK2. Other factors expressed in EMT, such as transforming growth factor beta (TGF-β), Snail Family Transcriptional Repressor 1 (Snai1), and Zinc finger E-box-binding homeobox 1 (Zeb1), have been associated with the arrest of the cell cycle by the inhibition of cyclin D1. However, Dawson *et al.* \[[@cit0085]\] showed that TB cells positive for ki67 and for caspase 3 were associated with an increased risk of death (odds ratio 9.1, *p* = 0.023).

Moreover, alterations of various proteins involved in apoptosis have been identified in TB cells. Apoptosis protease-activating factor-1 (Apaf-1) protein is a key regulator of the mitochondrial apoptotic pathway, being the central element of the multimeric complex called apoptosome, which is also formed by procaspase-9 and cytochrome c. This protein has been identified as diminished in tumours with high TB; concomitant decrease in B-cell lymphoma 2 (BCL2) has also been identified \[[@cit0086] --[@cit0088]\].

It has been described that the epithelial cells detached from the surrounding extracellular matrix undergo a physiological form of programmed cell death, termed anoikis \[[@cit0089], [@cit0090]\]. Thus, the tumour buds, as individual cells, must develop mechanisms of resistance to anoikosis if they are to survive during migration to the vessels and produce metastases. These mechanisms are complex and involve several signalling pathways that are closely related to EMT. Anoikosis avoidance could be an important factor in the biological behaviour of TB.

The role of the peritumoural stroma {#sec9.5}
-----------------------------------

The stroma seems to be a factor intimately involved with the process and maintenance of TB as well as favouring the dissemination of these cells. The role of CD10 expression in benign stromal cells has been studied in colorectal cancer \[[@cit0091]\]. It is postulated that due to the structural similarities between CD10 and MMP, CD10 could create a microenvironment that facilitates the invasion and metastasis of cancer cells. In addition, there is a strong relationship between the expression of MMP-9 in budding cells and a more aggressive tumour phenotype \[[@cit0092]\]. In some studies, the existence of different subtypes of stromal cells has been identified in the CRC with phenotypic and functional heterogeneity \[[@cit0040], [@cit0093]\].

Khanh *et al.* \[[@cit0094]\] found that overexpression of Mucin 1 (MUC1) cell surface-associated protein in the invasive tumour front was associated with TB and increased expression of TGF-β1, suggesting an immunosuppressive role of MUC1. In addition, these authors found a positive correlation of MUC1 with CD10 expression in the stromal cells of fibroblastic and myeloid phenotype, suggesting that MUC1+ cells interact with stromal cells favouring the EMT process.

Hypoxia and vascularisation {#sec9.6}
---------------------------

TB has also been associated with hypoxia-induced hypovascularisation in the advanced front of CRC. TB cells can escape hypoxia by expressing a hypoxic tumour phenotype mediated by hypoxia-induced factor 1a (HIF-1a), which increases its malignant potential \[[@cit0095]\]. In the stroma of the invading front, increased concentrations of TGF-β, a factor that induces vasculogenesis, as well as an increase in the number of capillary vessels have also been identified \[[@cit0096] --[@cit0098]\]. High levels of actin, heat shock protein 47 (HSP-47), and fibroblast growth factor (FGF) have also been identified in this stroma \[[@cit0099]\].

Association with miRNAs {#sec9.7}
-----------------------

Three studies have investigated the association of miRNAs in CCR. In a study in patients with rectal cancer, who received preoperative chemoradiotherapy, miRNA200c decrease was detected with high TB \[[@cit0055]\]. Another study conducted in patients with stage II and III colon cancer demonstrated a decrease in miRNA200b in patients with high TB \[[@cit0100]\]. Finally, in a CRC study, patients with high TB demonstrated a decrease in miRNA148a and miRNA6253p \[[@cit0101]\].

Limitations of the studies {#sec10}
==========================

Many of the series reviewed are not contemporary, in an era when the imaging or molecular studies were not very developed, the material corresponded to material stored several decades ago; in many there was no ideal preoperative staging and total mesorectal excision was not the standard surgery, so there was no adequate quality control. These are important limitations of the studies. In addition, many of them correspond to selected cases and where tumour stages are combined with a different prognosis.

Tumour budding in other cancers {#sec11}
===============================

The prognostic significance of tumour budding in CRC has stimulated research to determine its possible influence in other cancer types. Among the most comprehensively studied cancer sites are the oesophagus \[[@cit0102], [@cit0103]\], pancreas \[[@cit0104]--[@cit0106]\], head and neck \[[@cit0107]\], lung \[[@cit0108]\], and breast \[[@cit0109]\]. This research relied largely on concepts and methodologies developed in CRC studies. Consistently, in all these cancer sites, the high degree of TB has showed association with the previously discussed prognostic factors.

Conclusions {#sec12}
===========

There is evidence to suggest that TB is an adverse prognostic factor that can help stratify patients into more significant risk groups. However, more studies should be done to clarify its role in rectal cancer. For the considerable prognostic power of TB to be fully accepted, consensual and reproducible criteria must be established for its evaluation and reporting. While there is a recently published consensus, this is far from ideal. There are many unanswered questions about the genesis of these cells and the underlying molecular aspects, which, once explored, will give us more information about the tumour progression in rectal cancer.
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